Objective To explore syndrome and treatment law of TCM in treating pediatric pneumonia convalescence;To provide references for clinical syndrome differentiation and treatment.Methods The relevant literature about TCM in treating pediatric pneumonia convalescence was retrieved from CNKI,SinoMed,VIP,Wanfang Data and PubMed from the establishment of the databases to December 31,2024.Diagnostic basis,syndrome elements and TCM prescription information were extracted.Excel 2021 was used for frequency statistics,SPSS Modeler 18.0 was used for association rule analysis,Gephi 0.10.1 was used to complete complex network analysis,and Origin 2025 was used for data visualization.Results A total of 171 articles were included.Diagnosis basis predominantly involved symptoms,signs and course of the disease.TCM syndrome element distribution predominantly involved the lung,spleen,qi deficiency,yin deficiency,phlegm,dampness,blood stasis and heat,often presenting as a mixture of deficiency and excess patterns.A total of 98 prescriptions were collected,with high-frequency herbs primarily including tonifying and deficiency-replenishing herbs,and phlegm-resolving and antitussive herbs.The herbal properties and tastes were mainly warm,neutral,slightly cold,and sweet,bitter,pungent,primarily associated with the lung and spleen meridians.Complex network analysis identified three core patterns of syndrome-herb interactions.Conclusion The diagnosis of pediatric pneumonia convalescence relies on symptoms,signs and course of the disease as key criteria.The syndrome is often characterized by a deficiency-excess complex.Treatment should integrate the dynamic interactions among syndrome elements and adjust the balance between reinforcing healthy qi and eliminating pathogens based on the proportional weight of deficiency and excess.For deficiency patterns,it is necessary to focus on tonifying qi and nourishing yin.For concurrent syndromes or pathological factors,additional methods such as resolving phlegm,clearing heat,regulating qi,drying dampness,promoting digestion,cooling blood,and activating blood circulation may be incorporated.

Objective To explore syndrome and treatment law of TCM in treating pediatric pneumonia convalescence;To provide references for clinical syndrome differentiation and treatment.Methods The relevant literature about TCM in treating pediatric pneumonia convalescence was retrieved from CNKI,SinoMed,VIP,Wanfang Data and PubMed from the establishment of the databases to December 31,2024.Diagnostic basis,syndrome elements and TCM prescription information were extracted.Excel 2021 was used for frequency statistics,SPSS Modeler 18.0 was used for association rule analysis,Gephi 0.10.1 was used to complete complex network analysis,and Origin 2025 was used for data visualization.Results A total of 171 articles were included.Diagnosis basis predominantly involved symptoms,signs and course of the disease.TCM syndrome element distribution predominantly involved the lung,spleen,qi deficiency,yin deficiency,phlegm,dampness,blood stasis and heat,often presenting as a mixture of deficiency and excess patterns.A total of 98 prescriptions were collected,with high-frequency herbs primarily including tonifying and deficiency-replenishing herbs,and phlegm-resolving and antitussive herbs.The herbal properties and tastes were mainly warm,neutral,slightly cold,and sweet,bitter,pungent,primarily associated with the lung and spleen meridians.Complex network analysis identified three core patterns of syndrome-herb interactions.Conclusion The diagnosis of pediatric pneumonia convalescence relies on symptoms,signs and course of the disease as key criteria.The syndrome is often characterized by a deficiency-excess complex.Treatment should integrate the dynamic interactions among syndrome elements and adjust the balance between reinforcing healthy qi and eliminating pathogens based on the proportional weight of deficiency and excess.For deficiency patterns,it is necessary to focus on tonifying qi and nourishing yin.For concurrent syndromes or pathological factors,additional methods such as resolving phlegm,clearing heat,regulating qi,drying dampness,promoting digestion,cooling blood,and activating blood circulation may be incorporated.

ObjectiveTo identify the rate， population characteristics， and vaccination history of repeat infections among previously infected people in the current epidemic based on the rate of repeat infection and population characteristics of different mutant strains at different times in Pudong New Area of Shanghai， and to provide reference for the prevention and control strategies of novel coronavirus repeat infections. MethodsA total of 9 250 investigated subjects were randomly selected from the new cases of asymptomatic infection and confirmed cases reported by Pudong New Area from March to May 2022. The investigation mainly focused on demographic characteristics， nucleic acid or antigen test results， and symptoms after infection. The repeat infection rates among different populations were compared， and logistic regression was used to analyze the impact of gender， age， and vaccination status on repeat infections. ResultsThe survey sample of 9 250 people had a response rate of 81.85%. There were 4 043 males （53.40%） and 3 528 females （46.60%）， with a median age of 34 years old （P₂₅， P₇₅： 7， 61）. The overall vaccine uptake rate was 59.44% （4 500/7 571）. In December of 2022， there were 563 cases of repeat infection， with an infection rate of 7.44%. The lowest rate of repeat infection was seen in the 3‒ year-old group （2.86%） and the highest rate in the 30‒ year-old group （12.42%）， with significant differences between different age groups. The repeated infection rate for those who had completed their vaccinations was significantly lower （6.57%） compared to those who had not （7.11%）. The age groups of 3‒ years， 70‒79 years， as well as individuals who completed full vaccination and received booster shots were protective factors against repeat infections. ConclusionThe overall rate of reinfection among the infected in Shanghai during the spring of 2022 was low in the outbreak of the Omicron variant， and the rate of reinfection in the 3‒ year-old group was significantly lower than in other age groups. Completing the full course of vaccination significantly reduces the risk of reinfection. Although the reinfection rate is high in individuals who received booster shots， it remains a mitigating factor compared to those who do not receive the vaccine. It is recommended to continue monitoring reinfections in key populations and further strengthen immunization efforts.

Objective:To evaluate the efficacy of oliceridine for patient-controlled intravenous analgesia (PCIA) after bone tumor resection.Methods:In this prospective randomized controlled study, 72 patients of either sex, aged 18-64 yr, with a body mass index of 18-28 kg/m 2, of American Society of Anesthesiologists Physical Status classification Ⅰ-Ⅲ, who underwent elective bone tumor resection under general anesthesia, were selected and divided into 2 groups ( n=36 each) by the random number table method: sufentanil group (group S) and oliceridine group (group O). Combined intravenous-inhalational anesthesia was used in both groups. PCIA was performed from the end of surgery until 48 h after surgery. PCIA solution contained sufentanil 2 μg/kg in normal saline 100 ml in group S and oliceridine 0.4 mg/kg in normal saline 100 ml in group O. The background infusion rate was 2 ml/h, the bolus dose was 2 ml, the lockout interval was 15 min, and the maximum dose per hour was 10 ml in both groups. Flurbiprofen ester 50 mg was intravenously injected as rescue analgesic after operation when numerical rating scale score at rest≥4 or numerical rating scale score during activity≥7. The number of effective pressing times of patient-controlled analgesia (PCA), total pressing times of PCA, consumption of analgesics and requirement for rescue analgesia were recorded within 48 h after operation. Ramsay sedation scores were recorded at 2, 6, 12, 24 and 48 h after surgery. The occurrence of adverse reactions and requirement for rescue antiemetic within 48 h after surgery were recorded.The 15-item quality of recovery scale scores were assessed at 24 h before surgery and 24 and 48 h after surgery. The patient satisfaction score and satisfaction rate were recorded. Results:Compared with group S, the number of effective pressing times of PCA, total pressing times of PCA and consumption of analgesics were significantly reduced within 48 h after operation, the Ramsay sedation score was significantly increased at 12 h after surgery, the incidence of nausea and vomiting and rescue antiemetic rate were decreased, and the 15-item quality of recovery scale scores, satisfaction score and satisfaction rate were increased in group O ( P<0.05). There were no significant differences in the rate of rescue analgesia and incidence of respiratory depression, dizziness, pruritus and urinary retention within 48 h after operation ( P>0.05). Conclusions:Oliceridine has similar effect to sufentanil for postoperative PCIA, reduces the development of postoperative nausea and vomiting, improves satisfaction, and promotes early postoperative recovery when used in the patients undergoing bone tumor resection.

Objective:To evaluate the efficacy of oliceridine for patient-controlled intravenous analgesia (PCIA) after bone tumor resection.Methods:In this prospective randomized controlled study, 72 patients of either sex, aged 18-64 yr, with a body mass index of 18-28 kg/m 2, of American Society of Anesthesiologists Physical Status classification Ⅰ-Ⅲ, who underwent elective bone tumor resection under general anesthesia, were selected and divided into 2 groups ( n=36 each) by the random number table method: sufentanil group (group S) and oliceridine group (group O). Combined intravenous-inhalational anesthesia was used in both groups. PCIA was performed from the end of surgery until 48 h after surgery. PCIA solution contained sufentanil 2 μg/kg in normal saline 100 ml in group S and oliceridine 0.4 mg/kg in normal saline 100 ml in group O. The background infusion rate was 2 ml/h, the bolus dose was 2 ml, the lockout interval was 15 min, and the maximum dose per hour was 10 ml in both groups. Flurbiprofen ester 50 mg was intravenously injected as rescue analgesic after operation when numerical rating scale score at rest≥4 or numerical rating scale score during activity≥7. The number of effective pressing times of patient-controlled analgesia (PCA), total pressing times of PCA, consumption of analgesics and requirement for rescue analgesia were recorded within 48 h after operation. Ramsay sedation scores were recorded at 2, 6, 12, 24 and 48 h after surgery. The occurrence of adverse reactions and requirement for rescue antiemetic within 48 h after surgery were recorded.The 15-item quality of recovery scale scores were assessed at 24 h before surgery and 24 and 48 h after surgery. The patient satisfaction score and satisfaction rate were recorded. Results:Compared with group S, the number of effective pressing times of PCA, total pressing times of PCA and consumption of analgesics were significantly reduced within 48 h after operation, the Ramsay sedation score was significantly increased at 12 h after surgery, the incidence of nausea and vomiting and rescue antiemetic rate were decreased, and the 15-item quality of recovery scale scores, satisfaction score and satisfaction rate were increased in group O ( P<0.05). There were no significant differences in the rate of rescue analgesia and incidence of respiratory depression, dizziness, pruritus and urinary retention within 48 h after operation ( P>0.05). Conclusions:Oliceridine has similar effect to sufentanil for postoperative PCIA, reduces the development of postoperative nausea and vomiting, improves satisfaction, and promotes early postoperative recovery when used in the patients undergoing bone tumor resection.

Animals ; Antibodies, Neutralizing/biosynthesis* ; Antibodies, Viral/biosynthesis* ; Body Weight/immunology* ; COVID-19/virology* ; Disease Models, Animal ; Disease Progression ; Humans ; Immunohistochemistry ; Lung/virology* ; Male ; Mesocricetus ; Nasal Cavity/virology* ; RNA, Viral/immunology* ; SARS-CoV-2/pathogenicity* ; Severity of Illness Index ; Viral Load

OBJECTIVE： To prepare Baicalin-loaded Polyethylene glycol-derivatized phosphatidylethanolamine （BAI@PEG-PE） nanomicelles， and to characterize it and study its cytotoxicity. METHODS： BAI@PEG-PE nanomicelles were prepared by film hydration method and their appearance characteristics were observed. The particle size， polydispersity index， Zeta potential， drug-loading amount and encapsulation efficiency of the nanomicelles were detected. Drug release of BAI raw material and BAI@PEG-PE nanomicelles in pH 7.4 phosphate buffer were compared within 1-84 h. Using coumarin 6 as fluorescent probe， the distribution of PEG-PE nanomicelles in H9c2 cardiomyocytes were observed. H9c2 cardiomyocytes were divided into model group， BAI raw material group and BAI@PEG-PE nanomicelles group. After treated with serum-free DMEM medium containing no or corresponding drugs for 0.5 h， isoproterenol was used to induce cardiomyocyte apoptosis. Nuclear morphology， cell apoptosis rate and protein expression of Bcl-2 and Bax were compared with among 3 groups. RESULTS： Prepared BAI@PEG-PE nanomicelles were uniform globular shape. The particle size was （16.7±0.8） nm， PDI was 0.11±0.01 and Zeta-potential was （－18.4±0.6） mV； drug-loading amount was （7.84±0.65）％， encapsulation efficiency was （85.7±4.9）％ （n＝3）. Accumulative release rate was 76.5％ within 84 h. BAI raw material was released completely within 24 h. PEG-PE nanomicelles could strengthen the intake of coumarin 6 in H9c2 cardiomyocytes， mainly gathering around mitochondria. Compared with model group， the apoptosis morphology of cardiomyocytes were improved significantly in BAI raw material group and BAI@PEG-PE nanomicelles group； apoptosis rate was decreased significantly； protein expression of Bcl-2 was increased significantly； protein expression of Bax was decreased significantly with statistical significance （P＜0.05 or P＜0.01）. Above effects of BAI@PEG-PE nanomicelles group were more significant （P＜0.05 or P＜0.01）. CONCLUSIONS： BAI@PEG-PE nanomicelles are prepared successfully， and show significant sustained-release effect and myocardial targeting， and can prevent cardiomyocyte apoptosis.

Objective To report a pedigree with tyrosinemia type Ⅱ,and to analyze its causative mutations.Methods Clinical data were obtained from a 10-year-old male proband with tyrosinemia type Ⅱ,and analyzed retrospectively.Blood and urine samples were collected from 19 persons in 3 generations of the pedigree,and the amino acid level was detected in these samples.Genomic DNA was extracted from all of the 19 family members,and mutations in the tyrosine aminotransferase (TAT) gene were detected.Results The patient developed photophobia at 2 months after birth,and the symptom was gradually aggravated after that.At the age of 6 years,ocular pain and photophobia occurred.At the age of 8 years,linear keratotic plaques occurred on his fingertips and soles of both feet,with obvious tenderness.Ophthalmic examination showed no obvious abnormalities in corneal staining or ocular fundus.Skin examination showed multiple linear keratotic plaques on the fingers and soles of both feet.The serum tyrosine level was 825.64 μmol/L,and the level of p-hydroxyphenyllactic acid in urine was 161.4 μmol/L.Genetic testing showed 2 novel mutations,including c.236G ＞ A at position 236 in exon 2 of the TAT gene causing the substitution of glycine by glutamic acid (p.Gly79Glu),and c.1141G ＞ T at position 1141 in exon 10 of the TAT gene leading to the formation of a premature termination codon instead of glutamic acid (p.Glu381*).The proband was the only patient in the family.Some members in the patrilineal family carried the mutation c.1141G ＞ T (p.Glu381*),and some in the maternal family carried the mutation c.236G ＞ A (p.Gly79Glu).Conclusion This is the first case of tyrosinemia type Ⅱ reported in the domestic population,and 2 novel heterozygous mutations were identified in the TAT gene,which may lead to the occurrence of tyrosinemia type Ⅱ in the patient.

Background Idiopathic orbital inflammatory pseudotumor (IOIP) is a common orbital disease, but its etiology is still unclear,so the effect of glucocorticoid treatment is unsatisfied.Objective This study was to investigate the effects of dexamethasone on orbital fibroblasts from IOIP patients and explore the action machanism.Methods Six pieces of IOIP tissues from 6 IOIP patients and 3 pieces of normal orbital connective tissues from lacrimal gland prolapse patients were obtained during the surgery in Beijing Tongren Hospital from November 2011 to January 2012.The orbital fibroblasts were cultured using explant culture method.The morphology of the cells were observed under the optical microscope,and biomarks of the cells were detected by immunochemistry.The growth and proliferation of the cells were assayed using WST-8.The expression of ICAM-1 in the cells in both the control group and the IOIP group was detected by immunochemistry.The fibroblasts were incubated in 96-well plates, and different concentrations of dexamethasone (0,1 × 10-3 , 1 × 10-4 , 1 × 10-5 and 1 × 10-6 mol/L) were respectively added into the medium for 24,48 and 72 hours,and then the proliferation of the cells was detected by WST-8 assay.The contents of ICAM-1 in different concentrations of dexamethasone groups were assayed by ELISA.Results The characteristics of the cells were similar between the control group and the IOIP group with the spindle shape and long protructions.The cells showed the positive response for vimentin and absent response for desmin, S-100, cytokeratin (CK).Compared with the control group,the growth speed of fibroblasts was fast in the IOIP group.The proliferative values of the cells (absorbancy) were gradually reduced with the increase of dexamethasone concentrations (F ion =36.27,P=0.00) and the lapse of acting time (Ftime =3.69 ,P=0.00).In cultured cells without dexamethasone for 24,48 and 72 hours,the mean expression levels of ICAM-1 were 0.298±0.008,0.312±0.003 and 0.319±0.011, showing a gradually increasing trend.However,the expression of ICAM-1 was gradually reduced with the increases of concentrations and the lapse of acting time of dexamethasone (Fconcentration =75.17,P=0.00;Ftime =3.11,P=0.00).Conclusions Occurrence and development of IOIP is probably associated with the over-expression of ICAM-1 in orbital fibroblasts.Dexamethasone plays anti-inflammation and treating effects on IOIP by down-regulating the expression of ICAM-1 and inhibiting the proliferation of orbital fibroblasts.

We developed a high-sensitivity C-reactive protein quantifiable chemiluminescent immunoassay (hs-CRP CLIA). The high-purity native CRP was purified from hepatic cirrhosis patient ascetic fluid by affinity and ion exchange chromatography and used as an immunogen to develop the monoclonal antibodies (mAbs) against CRP. Twenty-two mAbs were identified reactive with CRP in ELISA and 13 of them were reactive in the phosphorycholine ligand capture ELISA. The mAbs 10C5 and 10C11 were selected to develop the hs-CRP CLIA. The linearity and performance of the hs-CRP CLIA was characterized. It was showed not reactive when testing against other serum materials (IgG, hemoglobin and triglyceride). The reliable correlation (R2 > 0.993) was obtained between testing value (RLU/S) and the concentration of human serum CRP calibrator. The linearity fell in the range of 0.04-20.38 mg/L. The assay has good accuracy and reproducibility, the mean recovery was 99% and the precision of the intra- and inter assay was CVs (4.2%-5.8%) and (9.0%-11.5%), respectively. In testing of 90 human sera, this assay performed well and correlated comparably with a commercial hs-CRP ELISA kit. Thus, hs-CRP CLIA is an accurate, reliable, quantifiable assay for detection of high-sensitive C-reactive protein in serum, it may be useful to improve the risk assessment of cardiovascular disease and the prognosis of inflammatory bowel disease.
C-Reactive Protein ; analysis ; chemistry ; Humans ; Immunoassay ; methods ; Luminescent Measurements ; methods ; Sensitivity and Specificity